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Editorial Comment
Defining the Role of Atrial
Natriuretic Factor in Health
And Disease*
THOMAS D. GILES, MD, FACC
New Orleans, Louisiana
No amount of experimentation can ever prove me right; a
single experiment can prove me wrong.
(Albert Einstein)
Historic perspective. Roach and coworkers (1) report in
this issue of the Journal the results of an elegant and difficult
investigation of the interaction between atrial natriuretic
factor (ANF) and the cardiopulmonary baroreceptor reflexes
in normal human subjects. These experiments were the
natural outgrowth of the demonstration over the past several
decades of the important role the atria play in both neuronal
and hormonal regulation of cardiovascular homeostasis. A
prominent role of the atria as sites for sensing changes in
central blood volume was demonstrated by Henry et al. (2)
in 1956 when they inflated a balloon in the left atrium of dogs
and observed an increase in urinary flow rate. They theo-
rized that the mechanism for this response involved a
neurogenic reflex, In the 1960s, de Wardener et al. (3)
suggested the existence of a circulating natriuretic substance
based on data from cross-circulation experiments in dogs
undergoing saline volume expansion. de Bold and colleagues
(4) reported in 1981 that crude extract from atria infused into
rats produced a 30-fold increase in both urinary sodium and
chloride excretion with impressive but less striking increases
in urinary flow rate and potassium excretion; the heart was
established as an endocrine organ. The atrial substance was
characterized as a peptide, which, together with its prohor-
mone, was soon sequenced (5). The peptide hormone has
variously been termed atrial natriuretic factor (ANF), atrial
natriuretic peptide (ANP), atriopeptin, cardioatrin, auriculin
and atrin. Atrial natriuretic factor has numerous biologic
actions including natriuresis, vasodilation (particularly of
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preconstricted vessels), increase in renal blood flow and
glomerular filtration rate and decrease in aldosterone pro-
duction, renin release, thirst and vasopressin secretion (6).
The physiologic role of the "low pressure" cardiopulmo-
nary baroreceptors (mechanoreceptors) in humans was clar-
ified when Roddie et al. (7) reported in 1957 that an increase
in central venous pressure achieved by passive leg raising
increased forearm blood flow without altering systemic
arterial pressure. Subsequent studies have demonstrated
that the low pressure cardiopulmonary baroreceptors are the
afferent source of an inhibitory reflex that governs sympa-
thetically controlled blood flow to skeletal muscle (8). Low
pressure cardiopulmonary baroreceptors are located promi-
nently in both atria as well as in ventricular endocardium and
the pulmonary circulation (8). In humans these barorecep-
tors regulate skeletal muscle blood flow with only a small
influence on splanchnic blood flow, heart rate and renin and
vasopressin release. In contrast, arterial ("high pressure")
baroreceptors or mechanoreceptors greatly influence heart
rate, splanchnic blood flow and renin and vasopressin secre-
tion. Afferent information from both the cardiopulmonary
and arterial baroreceptor systems is mediated through the
central nervous system cardiovascular control centers, par-
ticularly in the medulla and hypothalamus (9).
Cardiovascular homeostasis is achieved by the orchestra-
tion of neural and hormonal systems. Thus, the proximity of
the cardiopulmonary afferent receptors and ANF secretion
sites and the perceived importance of these two mechanisms
in intravascular volume control demanded that the potential
for interaction of these two systems be explored. A sym-
pathoinhibitory effect of ANF was suggested when its infu-
sion into experimental animals did not produce the expected
tachycardia despite reduction in systemic arterial blood
pressure (l0,11). Various studies supported the concept of
ANF-induced sympathoinhibition (10-17). These studies
generally involved doses of atrial natriuretic factor at the
higher end of the dose-effect curve, that is, pharmacologic
doses. The physiologic significance must not be disregarded
because pharmacology may often represent exaggerated
physiology.
Consideration of a neurally mediated role for ANF was
fueled by the finding of the hormone at many potential sites
for action. For example, ANF may either stimulate vagal
afferents or enhance the activity of mechanosensitive atrial
vagal fibers (11). Also, its binding sites are present in
presynaptic nerves and circumventricular organs such as the
subfornical organ and area postrema, areas important in
cardiovascular control and accessible to circulating atrial
natriuretic factor (18,19). To clarify the possible physiologic
and pathophysiologic significance of these observations,
Roach et al. (1) used ANF infusions at the lower end of the
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dose-effect curve (for blood concentrations in the patho-
physiologic range) to study the effects of the hormone on the
reflex response of selectively unloading the cardiopulmonary
mechanoreceptors by carefully regulated lower body nega-
tive pressure. Efferent sympathetic nerve activity was mea-
sured directly. These authors concluded that ANF is un-
likely to playa meaningful physiologic role in modulating
cardiopulmonary baroreceptor system activity.
Caution concerning this conclusion is advised because
under physiologic conditions ANF is released when cardio-
pulmonary mechanoreceptors are loaded (20,21), not un-
loaded. Thus, increased cardiopulmonary baroreceptor in-
hibitory input into cardiovascular control centers in the
central nervous system, such as the hypothalamus and
medulla, might influence the response to circulating ANF
(9).
The action of ANF on neural reflex mechanisms may also
depend on the status of the renin-angiotensin system. The
peptide is an endogenous antagonist to angiotensin II (6).
Binding sites of ANF and angiotensin II overlap in the brain,
kidney and adrenal cortex (22). A potential site for interac-
tion of ANF and the renin-angiotensin system in modulating
autonomic reflexes is the area postrema. Both ANF and
angiotensin II have binding sites in the area postrema;
angiotensin II stimulates the area postrema to produce
hemodynamic changes and modifies baroreceptor activity
(23). A possible role for ANF in modulating cardiopulmo-
nary baroreflexes needs to be studied under physiologic
modifications of atrial stretch and alterations of the renin-
angiotensin system. Such investigations will be aided by a
specific ANF antagonist.
Clinical relevance. Studies such as the one reported by
Roach et al. (1) are critical not only for understanding normal
cardiovascular physiology, but also for understanding the
pathophysiology of some diseases and for developing thera-
peutic strategies. Pathophysiologic states in which abnor-
malities in atrial natriuretic factor, cardiopulmonary barore-
ceptors and the renin-angiotensin system may coexist are
congestive heart failure and primary systemic arterial hyper-
tension.
In congestive heart failure, circulating ANF levels are
increased (24) and may be viewed as a counterregulatory
hormone providing a mechanism for vasodilation and salt
and water loss in opposition to vasoconstriction and salt
and water retention induced by activation of the renin-
angiotensin-aldosterone and sympathetic nervous systems
(25). Cardiopulmonary baroreceptor function is also abnor-
mal in congestive heart failure and may contribute to exces-
sive neurohumoral drive, with increased resistances in renal,
splanchnic and forearm vascular beds (8). In congestive
heart failure, increases in central blood volume and atrial
stretch convey information to the central nervous system
suggesting volume overload, and decreased activity by arte-
rial baroreceptors and decreased renal perfusion indicate
inadequate circulating blood volume. Thus, conflicting af-
ferent information may be presented to the central nervous
system. The counterregulatory importance of ANF in con-
gestive heart failure is indicated by hemodynamic worsening
in experimental animal models of congestive heart failure
that are given ANF monoclonal antibodies (26). Infusion of
ANF produces beneficial hemodynamic effects and salt and
water loss in patients with congestive heart failure (27),
although the effects may be blunted by down-regulation of
atrial natriuretic factor receptors (28). Increasing concentra-
tions of circulating atrial natriuretic factor may restore the
balance between opposing systems (29). Notably, the an-
giotensin-converting enzyme inhibitor captopril restores the
effectiveness of ANF in experimental congestive heart fail-
ure (30).
It is possible that ANF is involved in the pathophysiology
of hypertension (31), particularly when plasma renin activity
is low (32). Infusion of ANF has been found to reduce
systemic arterial blood pressure in experimental hyperten-
sive animals and in hypertensive humans. Cardiopulmonary
baroreceptor responses may also be abnormal in hyperten-
sion, that is, more sensitive during early hypertension, with
subsequent reduction as cardiac hypertrophy develops (33).
Studies of hypertension development in the Dahl salt-
sensitive rat (a low renin model of hypertension) indicate
abnormality of cardiopulmonary baroreceptor function and
ANF (34,35); the baroreflex impairment is aggravated by a
high-salt diet (36). Therefore, as in congestive heart failure,
the pathophysiologic interaction of ANF, cardiopulmonary
baroreceptors and the renin-angiotensin system is apparent.
Clearly, the cardiopulmonary and arterial baroreceptor
systems, atrial peptides and the renin-angiotensin-aldosterone
systems interact to regulate blood volume and pressure; other
factors or systems may await discovery. Much clinical value
has been derived from investigation of the renin-angiotensin-
aldosterone system; it is hoped that studies ofthe role ofANF
in health and disease will yield similar dividends. However,
the complexity of these factors requires that each pathophys-
iologic state be studied independently; extrapolation from
normal subjects to subjects with disease may be misleading.
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